Rhumbline Advisers Sells 3,110 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

Rhumbline Advisers trimmed its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 4.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 59,961 shares of the biopharmaceutical company’s stock after selling 3,110 shares during the quarter. Rhumbline Advisers owned approximately 0.12% of Theravance Biopharma worth $564,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. BNP Paribas Financial Markets increased its position in shares of Theravance Biopharma by 88.9% in the third quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock valued at $2,462,000 after acquiring an additional 143,781 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Theravance Biopharma by 2.9% in the third quarter. JPMorgan Chase & Co. now owns 266,879 shares of the biopharmaceutical company’s stock worth $2,151,000 after purchasing an additional 7,620 shares during the last quarter. GSA Capital Partners LLP increased its holdings in Theravance Biopharma by 12.6% during the 3rd quarter. GSA Capital Partners LLP now owns 229,780 shares of the biopharmaceutical company’s stock valued at $1,852,000 after purchasing an additional 25,691 shares during the period. Jane Street Group LLC raised its position in Theravance Biopharma by 1.1% during the 3rd quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock valued at $1,165,000 after purchasing an additional 1,640 shares during the last quarter. Finally, Algert Global LLC bought a new position in Theravance Biopharma during the 3rd quarter valued at approximately $851,000. 99.10% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $13.75.

Theravance Biopharma Price Performance

Shares of TBPH opened at $9.53 on Friday. The company has a 50-day simple moving average of $9.30 and a two-hundred day simple moving average of $8.97. The firm has a market capitalization of $468.63 million, a PE ratio of -9.44 and a beta of 0.21. Theravance Biopharma, Inc. has a one year low of $7.44 and a one year high of $10.90.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.26). The firm had revenue of $18.75 million for the quarter, compared to the consensus estimate of $29.90 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. Analysts expect that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Insider Activity

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at approximately $2,786,085. The trade was a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.90% of the company’s stock.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.